WHETHER PRIMARY TUMOR LOCALIZATION IS IMPORTANT FOR THE PREDICTION OF DRUG TREATMENT OF METASTATIC COLON CANCER?
- 作者: Dobrova N.V1, Borisova E.I1, Gutorov S.L1, Abramov M.E1
-
隶属关系:
- 期: 编号 17 (2016)
- 页面: 87-91
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289371
- ID: 289371
如何引用文章
详细
全文:
作者简介
N. Dobrova
Email: dobrova2008@rambler.ru
FSBI RORC n.a. N.N. Blokhin of RMH PhD, Senior Researcher at the Department of Chemotherapy and Combined Therapy of Malignant Tumors Moscow
E. Borisova
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
S. Gutorov
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
M. Abramov
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
参考
- Fleming M., Ravula S., Tatishchev S.F., Wang H.L. Colorectal carcinoma: pathologic aspects. J. Gastrointest. Oncol. 2012;3:153- 73.
- Hawkins N.J., Tomlinson I., Meagher A., Ward R.L. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br. J. Cancer. 2001;84:232-36.
- Russo A., Bazan V., Iacopetta B., Kerr D., Soussi T., Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 2005;23:7518-28.
- Nasir A., Kaiser H.E., Boulware D., Hakam A., Zhao H., Yeatman T., et al. Barthel J, Coppola D. Cyclooxygenase-2 expression in right- and leftsided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin. Colorectal Cancer. 2004;3:243-47.
- Watatani M., Yoshida T., Kuroda K., Ieda S., Yasutomi M. Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer. Cancer. 1996;77:1688-93.
- Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-60.
- Jacobs B., De Roock W., Piessevaux H., Van Oirbeek R., Biesmans B., De Schutter J., Fieuws S., Vandesompele J., Peeters M., Van Laethem J.-L., Humblet Y., P'enault-Llorca F., De Hertogh G., Laurent-Puig P., Van Cutsem E., Tejpar S. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 2009;27:5068-74.
- Pai R.K., Jayachandran P., Koong A.C., Chang D.T., Kwok S., Ma L., Arber D.A., Balise R.R., Tubbs R.R., Shadrach B. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am. J. Surg. Pathol. 2012;36:744-52.
- Popovici V., Budinska E., Bosman F.T., Tejpar S., Roth A.D., Delorenzi M. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer. 2013;13:439.
- Grimminger P.P., Shi M., Barrett C. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. Pharmacogenomics J. 2012;12: 404-13.
- Scartozzi M., Bearzi I., Mandolesi A., Giampier R., Faloppi L., Galizia E., Loupakis F., Zaniboni A., Zorzi F., Biscotti T., Labianca R., Falcone A., Cascinu S. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br. J. Cancer. 2011;104:1786-90.
- Guinney J., Dienstmann R., Wang X., de Reynies A., Schlicker A., Soneson C., Marisa L., Roepman P., Nyamundanda G., Angelino P., Bot B.M., Morris J.S., Simon I.M., Gerster S., Fessler E., DeSousa E., Melo F., Missiaglia E., Ramay H., Barras D., Homicsko K., Maru D., Manyam G.C., Broom B., Boige V., Perez-Villamil B., Laderas T., Salazar R., Gray J.W., Hanahan D., Tabernero J., Bernards R., Friend S.H., Laurent-Puig P., Medema J.P., Sadanandam A., Wessels L., Delorenzi M., Kopetz S., Vermeulen L., Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-56.
- Iacopetta B. Are there two sides to colorectal cancer? int. J. Cancer. 2002;101:403-8.
- Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr. Opin. Oncol. 2001;13:63-9.
- von Einem J.C., Heinemann V., Fischer von Weikersthal L., Vehling-Kaiser U., Stauch M., Hass H.G., Decker T., Klein S., Held S., Jung A., Kirchner T., Haas M., Holch J., Michl M., Aubele P., Boeck S., Schulz C., Giessen C., Stintzing S., Modest D.P. Leftsided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild type metastatic colorectal cancer treated with cetuximab plus chemotherapy:an analysis of the AiO KRK 0104 trial. J. Cancer Res. Clin. Oncol. 2014;140:1607-14.
- Missiaglia E., Jacobs B., Di Narzo A.F., Soneson C., Roth А., Bosman F., d'Ario G., Klingbiel D., Yan P., Delorenzi M., Tejpar S. Proximal and distal colon tumors as distinct biologic entities with different prognoses. J. Clin. Oncol. 2013;31(suppl; abstr 3526). epub 2013 ASCO annual Meeting.
- Brulé S.Y., Jonker D.J., Karapetis C.S., O'Callaghan C.J., Moore M.J., Wong R., Tebbutt N.C., Underhill Cr., Yip D., Zalcberg C.J., Tu D., Goodwin R.A. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCiC CO.17 EJS. 2015;51(issue 11):1405-14.
- Moretto R., Cremolini C., Rossini D., Pietrantonio F., Battaglin F., Mennitto A., Bergamo F., Loupakis F., Marmorino F., Berenato R., Valentina Angela Marsico V.A., Caporale M., Antoniotti C., Masi G., Salvatore L., Borelli B., Fontanini G., Lonardi S., De Braud F., Falcone A. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist. 2016;21:1-7.
- Wang F., Bai L., Liu T.-S., Yu Y.-Y., He M.-M., Liu K.-Y., Luo H.-Y., Zhang D.-S., Jin Y., Wang F.-H., Wang Z.-Q., Wang D.-S., Qiu M.-Z., Ren C., Li Y.-H., Xu R.-H. Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese J. Cancer. 2015;34:24.
- Brule S.Y., Jonker D.J., Karapetis C.S., O'Callaghan C.J., Moore M.J., Wong R., Tebbutt N.C., Underhill Cr., Yip D., Zalcberg C.J., Tu D., Goodwin R.A. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCiC CTG CO.17. J. Clin. Oncol. 2013;31:3528.
- Elsaleh H., Joseph D., Grieu F., Zeps N., Spry N., Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000;355:1745-50.
- Boisen M.K., Johansen J.S., Dehlendorff C., Larsen J.S., 0sterlind K., Hansen J., Nielsen S. E., Pfeiffer P., Tarpgaard L.S., Holländer N.H., Keldsen N., Hansen T.F., Jensen B.B., Jensen B.V. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann. Oncol. 2013;24:2554-59.
- Venook A.P., Niedzwiecki D., Innocenti F., Fruth D., Greene C., O'Neil B.H., Shaw J.E., Atkins J.N., Horvath L.E., Polite B.N., Meyerhardt J.A., O'Reilly E.M., Goldberg R.M., Hochster H.S., Blanke C.D., Schilsky R.L., Mayer R.J., Bertagnolli M.M., Lenz H.-J. impact of primary (1o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J. Clin. Oncol. 2016;(suppl; abstr 3504).
- Mais L., Bourien H., Aboudaram A., Lièvre A., Dupuy M., Francois E., Artru P., Senellart H., Coriat R., Edeline J., Guimbaud R., Samalin E., Desseigne F., Sarabi M., Guibert P., Ferlay C., De La Fouchardiere C. Analysis of medical practices for French patients with BRAF mutant metastatic colorectal cancer. J. Clin. Oncol. 2016;34(suppl; abstr e15070).